Suven Life up 4%, begins clinical trials of alzheimer drug

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Shares of Suven Life Sciences rallied more than 4 percent intraday Monday as the pharma company has initiated multiple ascending dose (MAD) studies in phase-I clinical trial.

"Suven has completed the single ascending dose (SAD) studies of SUVN-G3031 in healthy human volunteers and initiated multiple ascending dose studies (MAD) as a part of the phase I study currently ongoing in USA under US-IND 123179," said the company in its filing to the exchange.

SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of cognitive dysfunction associated with alzheimer’s disease and schizophrenia.

Suven said the phase-1 study was designed to evaluate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy volunteers. "The tolerability of SUVN-G3031 up to the highest dose administered in SAD study is excellent. No serious adverse events occurred. SUVN-G3031 demonstrated excellent pharmacokinetics with a potential for once in a day dosing," it added.

At 12:40 hours IST, the scrip of Suven Life Sciences was quoting at Rs 324.65, up Rs 6.90, or 2.17 percent on the BSE.

Posted by Sunil Shankar Matkar